Product Application

In the field of gastrointestinal cancer treatment, a target named CDH17 (cadherin-17, also known as liver-intestine cadherin) is rapidly emerging as a "golden track" that global pharmaceutical companies are competing to develop. From bispecific antibodies to antibody-drug conjugates (ADCs) and CAR-T cell therapies, drug development targeting CDH17 is advancing along multiple technological pathways with clinical progress. The recent blockbuster collaboration between Hansoh Pharma and Roche, involving a licensing deal worth up to $1.53 billion, has further thrust this target into the global biopharmaceutical spotlight.